MCT1 is a predictive marker for lenalidomide maintenance therapy in multiple myeloma

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Biomarkers predicting response to lenalidomide maintenance therapy in multiple myeloma (MM) are needed.
• Immunomodulatory drugs (IMiDs) like lenalidomide exert anti-MM activity by destabilizing MCT1 and CD147.
• Identifying predictive markers can optimize MM treatment strategies.

Purpose of the Study:

• To investigate MCT1 and CD147 expression as predictive biomarkers for response to maintenance therapy in multiple myeloma.
• To correlate MCT1 and CD147 expression with progression-free survival (PFS) and overall survival (OS) in MM patients.
• To functionally validate the role of MCT1 in predicting response to lenalidomide and bortezomib.

Main Methods:

• Gene expression profiling and RNA sequencing of cell samples from 654 MM patients.
• Correlation analysis of MCT1 and CD147 expression with PFS and OS data.
• In vitro and in vivo functional validation using MM cell lines and xenograft models.

Main Results:

• High MCT1 expression was significantly associated with reduced PFS and OS in patients receiving lenalidomide maintenance (P = .03 and P = .001, respectively).
• MCT1 expression did not significantly impact PFS or OS in patients receiving bortezomib maintenance.
• MCT1 overexpression reduced lenalidomide efficacy in vitro and in vivo, while bortezomib efficacy remained unaffected.
• MCT1's predictive role for IMiD-based maintenance was validated in an independent thalidomide-treated cohort.

Conclusions:

• MCT1 expression serves as a predictive biomarker for response to lenalidomide-based maintenance therapy in multiple myeloma.
• This discovery can guide treatment decisions and improve outcomes for MM patients.
• Targeting MCT1 or developing alternative therapies may be beneficial for patients with high MCT1 expression.